Global immunomodulators market is expected to witness a significant growth in coming seven years, due to increasing prevalence rate ofchronic diseases such as multiple sclerosis, cancer, asthma and other allergies induced by mold spores, dust mites and insect venom. Immunomodulators are fundamental agents of immunotherapy, helpful in stimulating immune system. The efficacy rate is enhanced with the use of immunotherapy techniques in combination with conventional treatment methods. Immunomodulatory regimens are an attractive approach as they have comparatively lesser side effects than existing drugs in the market thereby further increasing the demand for immunomodulators over the forecast period. However, stringent approval processes subjected to immunomodulators antibodies is expected to pose hurdle for market growth in coming seven years.
The overall global Immunomodulators market is bifurcated into immunosuppressant (interferon beta, antibodies, calcineurin inhibitors, glucocorticoids and antimetabolites) and immunostimulants (interferon alpha, vaccines and antibodies). Immunosuppressants have a broader spectrum drugs than immunostimulants. Immunosuppressants represents wider product portfolio such as antiproliferative drugs and antimetabolite drugs. Immunostimulants are expected to gain market share in coming seven years owing to its increasing usage in treatment of multiple sclerosis. Antimetabolites are expected to have a greater market share in case of immunosuppressants as it inhibits induction of contact hypersensitivity which is a common skin disease. Amongst immunostimulants, cancer vaccines and antibodies are expected to have a larger share in the growth of the market due to increasing incidence rate of cancer and allergies.Continuous research is going on with regard to effective use of immunomodulators in other medical conditions such as Alzheimer’s disease and diabetes which is further expected to drive overall immunomodulators market over the forecast period.
Geographically, the immunomodulatorsmarket is segmented into North America,Europe, Asia Pacific, Latin America and MEA. As of 2014, North America held the largest market share in immunomodulators marketdue to increasing incidence rate of cancer, asthma and various allergic diseases. Additionally, demand for immunomodulators in North America has increased due to rise in government funding and funds through private groups. European market is also expected to register growth due to rising healthcare infrastructure and supportive government policies. Asia Pacific countries such as India and China are expected to experience fastest growth due to rising demands for immunotherapy coupled with rising awareness amongst patients. Latin American market is witnessing a steady growth in the demands for immunomodulators owing to rising participation from the government and awareness among the people about availability of drugs.
The prominent players in immunomodulator market are Abbott, Novartis, Merck, Amgen, Hoffman La Roche, Biogen Idec, Eli Lilly, Bristol-Myers Squibb and Johnson & Johnson. The key market players are adopting competitive marketing strategies such as performingR&D operations and by entering into various strategic agreements. For example, Abbott and Biotest entered in to a marketing agreement of BT-061 in five European markets Germany, France, Spain, Italy and U.K. Key players are also focusing on new product development in order to increase their market penetration.
Grand View Research offers special pricing for:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.